Retatrutide Just Broke Every Obesity Record

Dr. Brad Stanfield — Retatrutide Just Broke Every Obesity Record

Channel: Dr Brad Stanfield · Our label: Physician educator — skeptical, evidence-first voice · Source: youtube.com/watch?v=ku8izA1Nh6o

What this video covers

Patients in a clinical trial are asking to stop their medication, not because of nausea, not because of cost, but because they’re losing far too much weight. The average patient in this trial lost 71 lb. 18% of patients on the highest dose, they discontinued partly because they were losing more weight than they had intended. Too effective is now a real clinical problem, but weight loss isn’t even the most surprising part of this drug.

Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.

Key points, in the speaker’s own framing

• Patients in a clinical trial are asking to stop their medication, not because of nausea, not because of cost, but because they’re losing far too much weight.
• These effects produced powerful weight loss, and it led to the development of semaglutide or Ozempic, which was approved in 2017.
• In the SURMOUNT-2 trial, tirzepatide tested specifically in people with obesity and type 2 diabetes, and the drug reached up to 15.7% weight loss at the highest dose.
• In the TRAILBLAZER-4 trial, 20.9% of patients on the highest dose reported a side effect that has got a clinical name that most people have never heard of, dysesthesia.
• So in an earlier phase 2 trial of retatrutide, there was evidence of elevated heart rate.
• So 18% of patients at the highest dose, they had to stop taking retatrutide, and some of them stopped because of the side effects, but others stopped because of what the trial reported as perceived excessive weight loss.

Read next

• GLP-1 class — more videos
• Semaglutide — more videos
• Tirzepatide — more videos
• Retatrutide — more videos
• All videos from this channel

Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.